Claims for Patent: 8,273,359

Summary for Patent: 8,273,359

Title:	Therapeutic use of at least one botulinum neurotoxin in the treatment of pain induced by at least one anti-neoplastic agent
Abstract:	The present invention relates to a method of treating or preventing pain or pains induced by an anti-neoplastic agent, comprising the step of administering an effective amount of at least one botulinum neurotoxin to a patient in need thereof.
Inventor(s):	Favre; Christine (Saint Maurice Montcouronne, FR), Auguet; Michel (Palaiseau, FR), Chabrier De Lassauniere; Pierre-Etienne (Paris, FR)
Assignee:	Ipsen Pharma S.A.S. (Boulogne Billancourt, FR)
Application Number:	12/447,443
Patent Claims:	1. A method of treating post-chemotherapy pain or pains in a patient in need thereof, comprising the step of administering by an intramuscular, intradermal, or subcutaneous route at least one botulinum neurotoxin at a dose between 0.01 to 1500 U, thereby providing systemic effect against the post-chemotherapy pain or pains. 2. The method of claim 1, wherein said post-chemotherapy pain or pains are induced by an anti-neoplastic agent or a salt thereof. 3. The method of claim 2, wherein said anti-neoplastic agent or salt thereof is a taxane, a platinum salt, or any combination thereof. 4. The method of claim 2, wherein said anti-neoplastic agent or salt thereof is docetaxel, paclitaxel, or any combination thereof. 5. The method of claim 3, wherein said anti-neoplastic agent or salt thereof is cisplatin, oxaliplatin, carboplatin, or any combination thereof. 6. The method of claim 2, wherein said anti-neoplastic agent or salt thereof is vincristine, vinblastine, etoposide, teniposide, Ara-A (adenoside-arabinoside), Ara-C (cytarabine), fluorouracil, procarbazine, vinorelbine, gemeitabine, or a mixture of paclitaxel and carboplatin, paclitaxel and an anthracycline, paclitaxel, carboplatin, and gemcitabine, paclitaxel and estramustine, docetaxel and cisplatin, docetaxel and doxorubicin, docetaxel and vinorelbine, docetaxel and trastuzumab, docetaxel and capecitabine, cisplatin and cyclophosphamide, cisplatin and irinotecan, carboplatin and topotecan, carboplatin and estramustine, etoposide and estramustine, or vinblastine and estramustine. 7. The method of claim 1, wherein said botulinum neurotoxin is of type A, A1, A2, B, C, C1, D, E, F or G. 8. The method of claim 7, wherein said botulinum neurotoxin is of type A1. 9. The method of claim 1, further comprising combining said botulinum neurotoxin with at least one polysaccharide. 10. The method of claim 9, wherein said at least one polysaccharide is 2-hydroxy-ethyl starch. 11. The method of claim 1, wherein said botulinum neurotoxin is a modified botulinum neurotoxin comprising at least one deleted, modified or replaced amino acid. 12. The method of claim 1, further comprising combining said botulinum neurotoxin with at least one surfactant. 13. The method of claim 12, wherein the at least one surfactant is a cationic, anionic, or non-ionic surfactant. 14. The method of claim 12, wherein the at least one surfactant is non-ionic and a polysorbate. 15. The method of claim 1, wherein said patient experiences post-chemotherapy pain or pains resulting from the treatment of cancers of the colon, rectum, breast, lungs, pancreas, testicles, kidney, uterus, ovary, prostate, skin, bones, or spinal cord or sarcomas, carcinomas, fibroadenomas, neuroblastomas, leukaemias, lymphomas, or melanomas. 16. A method of treating post-chemotherapy pain or pains in a patient in need thereof comprising the step of administering by an intramuscular, intradermal, or subcutaneous route at least one botulinum neurotoxin at a dose of 20 U/kg, thereby providing systemic effect against the post-chemotherapy pain or pains within 3 days from botulinum toxin injection.

Details for Patent 8,273,359

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2026-10-27
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2026-10-27
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2026-10-27